Vnitr Lek 2021, 67(2):e18-e24 | DOI: 10.36290/vnl.2021.029

Rheumatoid arthritis and metabolic disorders

Stela Kašperová1, Lenka Tarabčáková2, Barbora Kašperová3, Emőke Šteňová1
1 I. interná klinika Lekárskej fakulty Univerzity Komenského v Bratislave a Univerzitnej nemocnice v Bratislave
2 Reumatologická ambulancia, Nemocnica Sv. Michala, Bratislava
3 Klinika onkohematológie LF UK a NOÚ, Bratislava

Rheumatoid arthritis is a chronic autoimmune inflammatory disease associated with multiple metabolic alterations and increased cardiovascular risk. It is supposed that visceral obesity seems to be a connection between rheumatoid arthritis and cardiovascular diseases. Obesity is not only associated with increased disease activity and worsened quality of life in this group of patients, but also determines the effectiveness of treatment. Biological therapy interferes with metabolic changes, too. Therefore, there is a tendency to select the right anticytokine preparation in the first line of treatment to reduce not only disease activity but also affect aspects of metabolic syndrome and comorbidites, thereby reducing cardiovascular risk and patient's mortality. This work offers a basic overview of the associations between rheumatoid arthritis and metabolic disorders, describes the impact of biological therapy on individual components of the metabolic syndrome.

Keywords: anticytokine treatment, cardiovascular risk, metabolic syndrome, rheumatoid arthritis.

Published: April 21, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kašperová S, Tarabčáková L, Kašperová B, Šteňová E. Rheumatoid arthritis and metabolic disorders. Vnitr Lek. 2021;67(2):e18-24. doi: 10.36290/vnl.2021.029.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases 2017; 76(1): 17-28. Dostupné z DOI: http://dx.doi.org/10.1136/annrheumdis-2016-209775. Go to original source... Go to PubMed...
    2. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Annals of the Rheumatic Diseases 2014;73(1): 62-68. Dostupné z DOI: https:// 10.1136/annrheumdis-2013-204223. Go to original source... Go to PubMed...
    3. Houge, Ingrid Sæther, et al. Mortality is increased in patients with rheumatoid arthritis or diabetes compared to the general population-the Nord-Trøndelag Health Study. Scientific reports, 2020; 10(1): 1-10. Dostupné z DOI: https://doi.org/10.1038/s41598-020-60621-2. Go to original source... Go to PubMed...
    4. Kerekes, György, et al. Rheumatoid arthritis and metabolic syndrome. Nature Reviews Rheumatology, 2014; 10(11): 691. Dostupné z DOI: https://doi:10.1038/nrrheum.2014.121. Go to original source... Go to PubMed...
    5. Van Der Helm-Van Mil, A H M, et al. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Annals of the rheumatic diseases, 2008; 67(6): 769-774. Dostupné z DOI: https://doi:10.1136/ard.2007.078832. Go to original source... Go to PubMed...
    6. MacDonald, Iona J, et al. Associations between adipokines in arthritic disease and implications for obesity. International journal of molecular sciences, 2019; 20(6): 1505. Dostupné z DOI: https://doi:10.3390/ijms20061505. Go to original source... Go to PubMed...
    7. Dessein, Patrick H, et al. Rheumatoid arthritis impacts on the independent relationships between circulating adiponectin concentrations and cardiovascular metabolic risk. Mediators of inflammation, 2013, 2013. Dostupné z DOI: https://doi:10.1155/2013/461849. Go to original source... Go to PubMed...
    8. Lago, Francisca, et al. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine & growth factor reviews, 2007; 18(3-4): 313-325. Dostupné z DOI: https://doi:10.1016/j.cytogfr.2007.04.007. Go to original source... Go to PubMed...
    9. Francisco Vera, et al. Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases. Biochemical pharmacology, 2019. Dostupné z DOI: https://doi.org/10.1016/j.bcp.2019.03.030. Go to original source... Go to PubMed...
    10. Olama, Shereen M; Senna, Mohammed K; Elarman Mohammed. Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. Rheumatology International, 2012; 32(3): 683-690. Dostupné z DOI: https://doi.org/10.1007/s00296-010-1698-5. Go to original source... Go to PubMed...
    11. Tanti, Jean-François, et al. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Frontiers in endocrinology, 2013; 3: 181. Dostupné z DOI: https://doi.org/10.3389/fendo.2012.00181. Go to original source... Go to PubMed...
    12. Oravec S. Hyperlipoproteinémie, úvod do problematiky porúch metabolizmu lipoproteínov. Univerzita Komenského v Bratislave: 2012: 47-50. ISBN 978-80-223-3290-3.
    13. Charles-Schoeman, Christina, et al. Abnormal function of high - density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2009; 60(10): 2870-2879. Dostupné z DOI: https://doi.org/10.1002/art.24802. Go to original source... Go to PubMed...
    14. Ruscitti, Piero, et al. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS medicine, 2019, 16(9). Dostupné z DOI: https://doi:10.1371/journal.pmed.1002901. Go to original source... Go to PubMed...
    15. Everett, Brendan M, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. Journal of the American College of Cardiology, 2018; 71(21): 2392-2401. CANTOS. Dostupné z DOI: https://doi:10.1016/j.jacc.2018.03.002. Go to original source... Go to PubMed...
    16. Genovese, Mark C, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis & Rheumatology, 2015; 67(6): 1424-1437. Dostupné z DOI: https://doi.org/10.1002/art.39093. Go to original source... Go to PubMed...
    17. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Annals of the rheumatic diseases, 2009; 68(4): 460-469. Dostupné z DOI: http://dx.doi.org/10.1136/ard.2008.101964. Go to original source... Go to PubMed...
    18. Daïen, Claire Immediato, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Annals of the rheumatic diseases, 2012; 71(6): 862-868. Dostupné z DOI: http://dx.doi.org/10.1136/annrheumdis-2011-201148. Go to original source... Go to PubMed...
    19. Schultz O, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PloS one, 2010; 5(12). Dostupné z DOI: https://doi:10.1371/journal.pone.0014328. Go to original source... Go to PubMed...
    20. Szekanecz Z, et al. Autoimmune atherosclerosis in 3D: how it develops, how to diagnose and what to do. Autoimmunity reviews, 2016; 15(7): 756-769. Dostupné z DOI: https://doi.org/10.1016/j.autrev.2016.03.014. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.